Insights
Insights From Our Experts
Articles
How Pharma and PBMs Can Coexist and Lower Drug Costs Faster
The pharmaceutical industry and pharmacy benefit managers (PBMs) both play essential roles in getting medicines to patients. But years of complexity and competing incentives have strained the system. Our CEO Mark Thierer recently authored an article in Pharmaceutical Commerce, noting how meaningful progress will come not from…
Smarter, Faster, Compliant: Our Award-Winning Our AI-Powered Solutions Recognized in PM360’s Innovation Issue
In life sciences, speed and compliance aren’t optional, they’re mission-critical. Every delay in commercialization can cost millions, jeopardize launches, and ultimately impact patient access. At EVERSANA, we’ve reimagined the commercialization model with AI-powered solutions that deliver measurable impact: accelerating workflows, reducing costs,…
The Enablement Helix: An Evolving Framework for Market Success in Oncology
In today’s rapidly evolving oncology landscape, market success demands more than traditional promotional strategies – it requires a unified, cross-functional approach that empowers clinical partners and streamlines care delivery. EVERSANA’s dynamic framework, The Enablement Helix,…
Going Beyond Compliance: Transforming Aggregate Reports into Strategic Safety Intelligence
Posted on December 17, 202512/17/25
Leaders in today’s global pharmacovigilance (PV) teams are being pulled in two directions. On one side: the relentless demands of regulatory compliance. On the other hand, the growing need to act fast, make smarter decisions, and…
Digital-First Care and Affordability: Our Leaders Share Insights with pharmaphorum
Patients today expect care to be as seamless as buying online: on demand, transparent and personalized – pharma must adapt. Brian Laird, President, Patient Services, EVERSANA and Deanna Horner, SVP and Chief Pharmacy Officer, Waltz Health, explored how digital-first models, affordability…
Transitioning an Enterprise Literature Monitoring Program with EVERSANA ORCHESTRATE™ PV
How one enterprise client restored transparency and compliance in global literature monitoring Enterprise pharmacovigilance teams often face the challenge of managing high-volume literature surveillance while maintaining regulatory compliance and audit readiness. This case study highlights how…
Consolidating Data Strategy For Global Success
Data strategy isn’t just an operational detail, it’s the foundation of a successful global launch. Companies that neglect early planning risk costly missteps, from compliance gaps to duplicated investments. We believe data strategy is launch strategy. It’s what ensures evidence generation, regulatory…
Predicting PICOs for EU HTA: The Validated PICO Planner Approach Based on Retrospective Analysis
The EU Health Technology Assessment Regulation (EU HTAR) and Joint Clinical Assessment (JCA) aim to harmonize clinical evaluations across Europe while preserving national HTA decisions. To navigate this complexity, early and strategic PICO (Population, Intervention, Comparator,…
New Direct-to-Employer Access Model Provides Options for Employers to Improve Access to Weight Loss Medications
Waltz Health, an EVERSANA company, has introduced a new Direct-to-Employer (DTE) Access Model for FDA-approved obesity management medicines. The model, developed in collaboration with leading drug manufactures including Eli Lilly and Novo Nordisk, gives employers a new,…
Pharmatizing AI: How Artificial Intelligence Is Transforming Pharma
From discovery to delivery, artificial intelligence is reshaping how pharma works—and the change is accelerating. As Global Co-Host and Presenting Sponsor of Frontiers Health 2025, our team led a critical conversation on AI in pharma. With Roberto Ascione, President…